Dual therapy with dolutegravir plus lamivudine as first-line ART
1 October 2017. Related: Conference reports, Antiretrovirals.
Conference reports
Once-daily raltegravir: 96-week results from the ONCEMRK study
1 October 2017. Related: Conference reports, Antiretrovirals.
New IPERGAY analysis shows on-demand PrEP dosing works with less frequent sex
1 October 2017. Related: Conference reports, HIV prevention and transmission.
On-demand dosing for PrEP is highly effective in French expanded access programme
1 October 2017. Related: Conference reports, HIV prevention and transmission.
Psychological impact of PrEP: beyond efficacy and cost-effectiveness
1 October 2017. Related: Conference reports, HIV prevention and transmission.
Early ART and testing HIV negative with rapid HIV tests
1 October 2017. Related: Conference reports, HIV prevention and transmission.
Report from the IAS HIV Cure & Cancer Forum, 22–23 July 2017, Paris
1 October 2017. Related: Conference reports, Cancer and HIV, Cure-related research.
9th IAS Conference on HIV Science (IAS 2017)
10 August 2017. Related: Conference reports.
HIV pipeline drugs: IAS 2017 update
10 August 2017. Related: Conference reports, Antiretrovirals.
Darunavir/cobicistat/FTC/TAF: 24-week interim results from phase 3 switch study
10 August 2017. Related: Conference reports, Antiretrovirals.
Phase 3 results with bictegravir FDC: a new integrase inhibitor combined with FTC/TAF
10 August 2017. Related: Conference reports, Antiretrovirals.
Doravirine/3TC/TDF compared to efavirenz/FTC/TDF as first-line ART
10 August 2017. Related: Conference reports, Antiretrovirals.
Continued viral suppression with long-acting cabotegravir/rilpivirine injections: 96-week LATTE-2 results
10 August 2017. Related: Conference reports, Antiretrovirals.
Reduced-dose darunavir is safe and effective in switch study
10 August 2017. Related: Conference reports, Antiretrovirals.
MK-8591: further compelling early results for both treatment and prevention
10 August 2017. Related: Conference reports, Antiretrovirals, HIV prevention and transmission.
Dolutegravir outperforms lopinavir/ritonavir second-line: interim results from the DAWNING study
10 August 2017. Related: Conference reports, Antiretrovirals, Treatment strategies, Treatment access.
Preliminary results on dolutegravir use in pregnancy are reassuring
10 August 2017. Related: Conference reports, Pregnancy.
Low dose efavirenz (EFV400) can be used during pregnancy
10 August 2017. Related: Conference reports, Pregnancy.
Stillbirth rate in HIV positive women in UK/Ireland is double that of the general population
10 August 2017. Related: Conference reports, Pregnancy.
Swaziland nearly halves HIV incidence in five years
10 August 2017. Related: Conference reports, Treatment access.
Gay men with undetectable viral load do not transmit HIV: Opposites Attract study supports U=U
10 August 2017. Related: Conference reports, HIV prevention and transmission.
HIV remission news from IAS 2017
10 August 2017. Related: Conference reports, Cure-related research, Basic science and immunology.
Publications launched at IAS 2017
10 August 2017. Related: Conference reports, Drug resistance, Other news.
9th International Workshop on HIV Paediatrics, 21–22 July 2017, Paris
10 August 2017. Related: Conference reports, Paediatric care.
Chewable raltegravir tablets can be crushed and dispersed in liquid for young children
10 August 2017. Related: Conference reports, Paediatric care.
Inconsistencies between real-world data from UK and Ireland and EU recommendations for new antiretrovirals in pregnancy
10 August 2017. Related: Conference reports, Pregnancy.
18th International Workshop on Clinical Pharmacology of Antiviral Therapy, 14-16 June 2017, Chicago
26 June 2017. Related: Conference reports.
Dolutegravir pharmacokinetics in pregnancy
26 June 2017. Related: Conference reports, Antiretrovirals, Pregnancy, PK and drug interactions.
High rates of of undocumented efavirenz-related side effects in Uganda
26 June 2017. Related: Conference reports, Antiretrovirals, Side effects.
11th INTEREST Workshop, 16-19 May 2017, Lilongwe, Malawi
26 June 2017. Related: Conference reports.
Increased risk of ART failure after low-level viraemia in a large South African cohort
26 June 2017. Related: Conference reports, Antiretrovirals.
Option B+ Malawi
26 June 2017. Related: Conference reports, Antiretrovirals, Pregnancy.
24th Conference on Retroviruses and Opportunistic Infections (CROI 2017), 13-16 February 2017, Seattle
26 June 2017. Related: Conference reports.
Impressive HIV pipeline at CROI 2017
26 June 2017. Related: Conference reports, Coinfections and complications.
Paediatric HIV: CROI 2017
26 June 2017. Related: Conference reports, Coinfections and complications.
23rd Annual Conference of BHIVA, 4-7 April 2017, Liverpool
24 April 2017. Related: Conference reports.
Drop in HIV incidence in gay men: frequent testing, early ART and PrEP
24 April 2017. Related: Conference reports, Antiretrovirals, HIV prevention and transmission.
Prompt/early ART: Dean Street pilot project reports 75% uptake
24 April 2017. Related: Conference reports, Antiretrovirals.
Potential for phylogenetic analysis to show direction of HIV transmission
24 April 2017. Related: Conference reports, HIV prevention and transmission.
Community presentations: dental care, HIV awareness and access to formula milk
24 April 2017. Related: Conference reports, Paediatric care.
Initiatives for earlier HIV diagnosis: opt-out ER and home testing
24 April 2017. Related: Conference reports, HIV prevention and transmission.
No new HIV cases in 398 people using PrEP at Dean Street clinic
24 April 2017. Related: Conference reports, HIV prevention and transmission.
Other selections and webcasts
24 April 2017. Related: Conference reports, Antiretrovirals, Coinfections and complications, Hepatitis coinfection, Cure-related research.
24th Conference on Retroviruses and Opportunistic Infections (CROI 2017), 13-16 February 2017, Seattle
24 April 2017. Related: Conference reports.
Dose reduction potential of nanoparticle ARV formulations confirmed in humans
24 April 2017. Related: Conference reports, Antiretrovirals.
VRC01 in HIV-exposed newborns: first results support monthly injections for those at risk through breastfeeding
24 April 2017. Related: Conference reports, Antiretrovirals, Pregnancy, Paediatric care.
Raltegravir pharmacokinetic targets met in high-risk HIV-exposed infants
24 April 2017. Related: Conference reports, Antiretrovirals, Paediatric care, PK and drug interactions.
Tenofovir alafenamide exposure is modestly higher in children than adults
24 April 2017. Related: Conference reports, Antiretrovirals, Paediatric care.
New HIV diagnoses in children in UK and Ireland continue to decline
24 April 2017. Related: Conference reports, Paediatric care, PK and drug interactions, Diagnostics.
World Health Organisation paediatric dosing tool
24 April 2017. Related: Conference reports, Paediatric care, PK and drug interactions.
Pre-ART drug resistance in rural South Africa but limited clinical impact with good adherence
24 April 2017. Related: Conference reports, Antiretrovirals, Drug resistance.
Immune-based therapy canakinumab reduces inflammatory markers in HIV positive people on ART
24 April 2017. Related: Conference reports, Treatment strategies, Basic science and immunology.
Significant interaction between once-weekly isoniazid/rifapentine and daily dolutegravir: study stopped due to toxicity
24 April 2017. Related: Conference reports, PK and drug interactions.
Increased risk of IRIS with integrase inhibitors reported in two studies
24 April 2017. Related: Conference reports, Antiretrovirals, Treatment strategies, Coinfections and complications.
Breakthrough for treating XDR-TB and ameliorating TB-IRIS
24 April 2017. Related: Conference reports, Coinfections and complications, TB coinfection.
PrEP in pregnancy does not increase poor birth outcomes
24 April 2017. Related: Conference reports, Pregnancy, HIV prevention and transmission.
HIV cure research and basic science: capsules from CROI 2017
24 April 2017. Related: Conference reports, Cure-related research, Basic science and immunology.
24th Conference on Retroviruses and Opportunistic Infections (CROI 2017), 13-16 February 2017, Seattle
27 February 2017. Related: Conference reports.
Pharmacokinetics and full phase 2 results for bictegravir, a new integrase inhibitor
27 February 2017. Related: Conference reports, Antiretrovirals, PK and drug interactions.
New NNRTI doravirine is non-inferior to darunavir/r in phase 3 treatment naive study
27 February 2017. Related: Conference reports, Antiretrovirals.
NRTI GS-9131 resurfaces at CROI 2017: in vitro sensitivity to nuke-resistant HIV
27 February 2017. Related: Conference reports, Antiretrovirals.
Dolutegravir exposure increases when fixed dose combination tablets are crushed
27 February 2017. Related: Conference reports, Antiretrovirals, Paediatric care.
Pharmacokinetics, safety and efficacy of dolutegravir in very young children
27 February 2017. Related: Conference reports, Antiretrovirals, Paediatric care.
Efavirenz, tenofovir and emtricitabine associated with fewest adverse birth outcomes in Botswana
27 February 2017. Related: Conference reports, Antiretrovirals, Pregnancy.
Adverse pregnancy outcomes and risk factors in the PROMISE trial
27 February 2017. Related: Conference reports, Antiretrovirals, Pregnancy.